Agios Pharmaceuticals
Open
$28.21
Prev. Close
$28.22
High
$28.22
Low
$28.17
Market Snapshot
$1.64B
-4.0
11.79
$36.5M
540
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. The company is headquartered in Cambridge, Massachusetts and currently employs 539 full-time employees. The company went IPO on 2013-07-24. The firm is focused on developing and delivering transformative therapies for patients living with rare diseases. The company markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. The company is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Agios Pharmaceuticals reported Q4 2025 revenue of $19.97 million, with a basic earnings per share loss of $1.85 reflecting ongoing financial challenges.
Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. The company is headquartered in Cambridge, Massachusetts and currently employs 539 full-time employees. The company went IPO on 2013-07-24. The firm is focused on developing and delivering transformative therapies for patients living with rare diseases. The company markets a first-in-class pyruvate kinase (PK) activator for adults with PK deficiency, the first disease-modifying therapy for debilitating hemolytic anemia. Its lead product candidate in its portfolio, PYRUKYND (mitapivat), is an activator of both wild-type and mutant pyruvate kinase, or PK, enzymes for the potential treatment of hemolytic anemias. The company is also developing tebapivat, a novel PK activator, for the potential treatment of lower-risk myelodysplastic syndromes, or LR MDS, and hemolytic anemias; AG-181, its phenylalanine hydroxylase, or PAH, stabilizer for the potential treatment of phenylketonuria, or PKU; and AG-236, an siRNA in-licensed from Alnylam Pharmaceuticals, Inc., targeting the transmembrane serine protease 6, or TMPRSS6 gene for the potential treatment of polycythemia vera, or PV.
Recently from Cashu
FDA Encourages Agios Pharmaceuticals on Mitapivat for Sickle Cell Disease Approval and Market Access
Agios Pharmaceuticals receives significant encouragement from the FDA regarding its drug mitapivat, designed to treat sickle cell disease. This pivotal moment occurs after a pre-supplemental New Drug…
Agios Pharmaceuticals Advances Mitapivat's Regulatory Journey for Sickle Cell Disease Treatment
Agios Pharmaceuticals Advances Regulatory Pathway for Mitapivat Agios Pharmaceuticals is making notable strides in the regulatory journey for mitapivat, an oral pyruvate kinase activator aimed at trea…
Agios Pharmaceuticals Under Investigation After Disappointing Phase 3 Trial Results for Mitapivat
Agios Pharmaceuticals Faces Scrutiny Over Phase 3 Trial Results Agios Pharmaceuticals, a biopharmaceutical company known for its innovative approaches to treating rare diseases, finds itself under inv…
Agios Pharmaceuticals Faces Investigation as Shareholders Pursue Legal Action for Possible Securities Fraud
Investigation into Agios Pharmaceuticals Sparks Legal Action Among Shareholders In a notable development for Agios Pharmaceuticals, The Gross Law Firm has initiated an investigation into potential sec…